NCT05918523Recruiting
A Long-Term Follow-Up Study of Participants Exposed to REACT
A Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy From Studies RMCL-002, REGEN-003, REGEN-004
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 15 Jun 2023
- Start date
- Dec 2023
- Primary completion date
- Jan 2028
- Lead sponsor
- Prokidney
- Diseases
- Chronic kidney disease
- NCT number
- NCT05918523
What you commit to
- Study type: Observational
- Planned participants: 80
- From Dec 2023 to the primary completion date, Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.
Who the study is looking for
- The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.
Age in the registry: 30 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Boise Kidney & Hypertension Institute Coordinator of this site? Confirm its status | Meridian | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.